Key Laboratory of UV-Emitting Materials and Technology (Northeast Normal University), Ministry of Education, Changchun, Jilin 130024, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Nano Lett. 2023 May 24;23(10):4191-4200. doi: 10.1021/acs.nanolett.3c00071. Epub 2023 May 15.
Multispecific antibodies (MsAbs) maintain the specificity of versatile antibodies while simultaneously addressing different epitopes for a cumulative, collaborative effect. They could be an alternative treatment to chimeric antigen receptor-T cell therapy by helping to redirect T cells to tumors . However, one major limitation of their development is their relatively complex production process, which involves performance of a massive screen with low yield, inconsistent quality, and nonnegligible impurities. Here, a poly(l-glutamic acid)-conjugated multiple Fc binding peptide-based synthesis nanoplatform was proposed, in which MsAbs were constructed by mixing the desired monoclonal antibodies (mAbs) with polymeric Fc binding peptides in aqueous solution without purification. To determine its efficacy, a dual immune checkpoint-based PD1/OX40 bispecific antibody and PDL1/CD3e/4-1BB trispecific antibody-based T cell engager were generated to trigger antitumor CD8 T responses in mice, showing superior tumor suppression over free mixed mAbs. In this study, a facile, versatile build platform for MsAbs was established.
多特异性抗体 (MsAbs) 在保持多功能抗体特异性的同时,针对不同表位发挥累积协同作用。它们可以替代嵌合抗原受体-T 细胞疗法,通过帮助将 T 细胞重新导向肿瘤。然而,其发展的一个主要限制是其相对复杂的生产过程,涉及大规模筛选,产量低、质量不一致且不可忽略的杂质。在这里,提出了一种聚(L-谷氨酸)-缀合的多个 Fc 结合肽基合成纳米平台,其中 MsAbs 通过将所需的单克隆抗体 (mAbs) 与聚合物 Fc 结合肽在水溶液中混合而构建,无需纯化。为了确定其疗效,生成了基于双重免疫检查点的 PD1/OX40 双特异性抗体和 PDL1/CD3e/4-1BB 三特异性抗体的 T 细胞衔接子,以在小鼠中引发抗肿瘤 CD8 T 反应,显示出优于游离混合 mAbs 的肿瘤抑制作用。在这项研究中,建立了一种简便、通用的 MsAbs 构建平台。